Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ATXINASDAQ:KZIANASDAQ:ONVONASDAQ:PALI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATXIAvenue Therapeutics$0.25+0.8%$0.60$0.25▼$8.99$794K0.1142,836 shs26,263 shsKZIAKazia Therapeutics$3.67+7.2%$4.15$2.86▼$79.00$3.69M2.28172,435 shs87,665 shsONVOOrganovo$3.94$1.56▼$21.96$3.47M1.13617,505 shs243,634 shsPALIPalisade Bio$0.73-1.0%$0.78$0.60▼$9.09$3.20M1.5539,709 shs23,609 shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATXIAvenue Therapeutics-3.06%-5.66%-31.10%-86.77%-96.46%KZIAKazia Therapeutics+2.70%+3.64%-30.92%-59.76%-82.42%ONVOOrganovo0.00%+18.60%-28.17%-50.29%-83.00%PALIPalisade Bio+3.94%+2.17%+6.58%-51.61%-88.42%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationATXIAvenue Therapeutics2.6206 of 5 stars0.05.00.04.62.10.01.9KZIAKazia Therapeutics2.8049 of 5 stars3.55.00.00.00.60.00.0ONVOOrganovo0.5228 of 5 stars0.03.00.00.02.40.00.6PALIPalisade Bio2.8144 of 5 stars3.55.00.00.02.10.01.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATXIAvenue Therapeutics 0.00N/AN/AN/AKZIAKazia Therapeutics 3.00Buy$57.501,444.04% UpsideONVOOrganovo 0.00N/AN/AN/APALIPalisade Bio 3.00Buy$23.002,966.67% UpsideCurrent Analyst Ratings BreakdownLatest ATXI, PALI, KZIA, and ONVO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails2/6/2025KZIAKazia TherapeuticsMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$15.00(Data available from 4/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATXIAvenue TherapeuticsN/AN/AN/AN/A$1.92 per shareN/AKZIAKazia Therapeutics$2.31M1.62N/AN/A($1.97) per share-1.89ONVOOrganovo$122K0.00N/AN/A$0.02 per share0.00PALIPalisade Bio$250K13.19N/AN/A$18.29 per share0.04Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATXIAvenue Therapeutics-$10.38M$18.350.01∞N/AN/A-471.57%-296.50%5/13/2025 (Estimated)KZIAKazia Therapeutics-$17.56MN/A0.00∞N/AN/AN/AN/A4/25/2025 (Estimated)ONVOOrganovo-$14.67M-$10.20N/AN/AN/A-10,151.64%-346.26%-187.53%5/30/2025 (Estimated)PALIPalisade Bio-$12.30M-$10.92N/AN/AN/AN/A-148.51%-115.16%5/12/2025 (Estimated)Latest ATXI, PALI, KZIA, and ONVO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025N/APALIPalisade Bio-$0.84N/AN/AN/AN/AN/A3/24/2025Q4 2024PALIPalisade Bio-$2.39-$0.69+$1.70-$0.69N/AN/A2/19/2025Q3 2025ONVOOrganovo-$2.52-$2.28+$0.24-$0.19$0.05 million$0.02 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATXIAvenue TherapeuticsN/AN/AN/AN/AN/AKZIAKazia TherapeuticsN/AN/AN/AN/AN/AONVOOrganovoN/AN/AN/AN/AN/APALIPalisade BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATXIAvenue TherapeuticsN/A2.702.70KZIAKazia TherapeuticsN/A0.240.24ONVOOrganovoN/A0.721.72PALIPalisade BioN/A3.313.31Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATXIAvenue Therapeutics17.34%KZIAKazia Therapeutics30.89%ONVOOrganovo8.23%PALIPalisade Bio11.79%Insider OwnershipCompanyInsider OwnershipATXIAvenue Therapeutics1.80%KZIAKazia Therapeutics1.00%ONVOOrganovo3.72%PALIPalisade Bio3.28%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATXIAvenue Therapeutics43.15 million2.02 millionNot OptionableKZIAKazia Therapeutics121.01 million4.99 millionOptionableONVOOrganovo201.70 million14.79 millionOptionablePALIPalisade Bio104.40 million2.68 millionNot OptionableATXI, PALI, KZIA, and ONVO HeadlinesRecent News About These CompaniesHyundai’s Next-Gen Hybrid System Offers 45% Boost In Fuel EfficiencyApril 21, 2025 | msn.comPalisade completes dosing in Phase 1b portion of Phase 1a/1n study of PALI-2108April 9, 2025 | markets.businessinsider.comPalisade Bio Completes Dosing in Phase 1a Portion of Ongoing Phase 1a/b Study of PALI-2108April 9, 2025 | globenewswire.comMaxim Group Sticks to Their Buy Rating for Palisade Bio (PALI)March 27, 2025 | markets.businessinsider.comPalisade Bio begins dosing subjects in last cohort of ulcerative colitis drug trialMarch 17, 2025 | finance.yahoo.comPalisade Bio commences dosing in first UC patient cohort in study of PALI-2108March 14, 2025 | markets.businessinsider.comPalisade Bio Reports Encouraging Preliminary Safety and Tolerability Data for PALI-2108 in Phase 1a/b Study for Ulcerative ColitisMarch 14, 2025 | quiverquant.comPalisade Bio Commences Dosing in First Ulcerative Colitis Patient Cohort in Ongoing Phase 1a/b Study of PALI-2108March 14, 2025 | globenewswire.comPalisade Bio Announces Two Abstracts Selected to be Showcased as Poster of Distinction and Poster Presentation at Leading GI Forum, Digestive Disease Week (DDW) 2025March 12, 2025 | globenewswire.comPalisade Bio (PALI) Upgraded to Buy: What Does It Mean for the Stock?March 7, 2025 | zacks.comPalisade Bio Participates in Virtual Investor “What This Means” SegmentMarch 4, 2025 | globenewswire.comPalisade Bio receives cash proceeds from Canada’s SR&ED tax incentive programFebruary 20, 2025 | markets.businessinsider.comPalisade Bio Secures CAD$1.39 Million in SR&ED Funding for PALI-2108 Development EffortsFebruary 20, 2025 | quiverquant.comPalisade Bio, Inc. Announces Receipt of Cash Proceeds from Canada's SR&ED Tax Incentive Program for Reimbursement of Development Costs of PALI-2108 for Treatment of Ulcerative Colitis (UC)February 20, 2025 | globenewswire.comPalisade Bio, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand ConferenceFebruary 19, 2025 | globenewswire.comPalisade Bio presents preclinical data of PALI-2108February 10, 2025 | markets.businessinsider.comPalisade Bio Presents Positive Preclinical Data for PALI-2108 in Ulcerative Colitis at 2025 Crohn’s and Colitis CongressFebruary 10, 2025 | quiverquant.comPalisade Bio Presents Positive Preclinical Data of PALI-2108 for the Treatment of Ulcerative ColitisFebruary 10, 2025 | globenewswire.comPalisade Bio Selected for Poster Presentation at the 2025 Crohn’s & Colitis CongressJanuary 30, 2025 | markets.businessinsider.comPalisade Bio Selected for Poster Presentation at the 2025 Crohn's & Colitis CongressJanuary 29, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeATXI, PALI, KZIA, and ONVO Company DescriptionsAvenue Therapeutics NASDAQ:ATXI$0.25 +0.00 (+0.76%) As of 01:27 PM EasternAvenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders. The company was incorporated in 2015 and is based in Bay Harbor Islands, Florida.Kazia Therapeutics NASDAQ:KZIA$3.66 +0.25 (+7.16%) Closing price 03:51 PM EasternExtended Trading$3.65 -0.02 (-0.41%) As of 06:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Kazia Therapeutics Limited operates as an oncology-focused biotechnology company. The company's lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.Organovo NASDAQ:ONVOOrganovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive 3D bioprinted human liver tissue with distinct hepatocellular and non-parenchymal cell compartments. The company was incorporated in 2007 and is headquartered in San Diego, California.Palisade Bio NASDAQ:PALI$0.73 -0.01 (-1.02%) Closing price 03:53 PM EasternExtended Trading$0.74 +0.01 (+1.10%) As of 07:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor, currently under pre-clinical development as a therapeutic for patients living with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease (CD), as well as develops PALI-1908, an oral, selective PDE4 inhibitor prodrug that is locally bioactivated in the terminal ileum of CD patients, currently in the research stage. It has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; a license agreement with the Regents of the University of California; a co-development and distribution agreement with Newsoara Biopharma Co., Ltd; and a transformative strategic collaboration with Strand Life Sciences for advancing precision medicine for ulcerative colitis therapy. The company is based in Carlsbad, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas If You Wanted To Buy AbbVie and Didn’t, There’s Still Time To Buy 3 Stocks To Watch For When Tariffs Subside 3 Boring Stocks Outperforming the Market This Year Short Sellers Gave Up on These 3 Names Recently Market Anticipation Builds: Joby Stock Climbs Ahead of Earnings Is Intuitive Surgical a Buy After Volatile Reaction to Earnings? Now Is the Time to Buy ServiceNow—The Rebound Is Real Archer Aviation Gets Analyst Target Upgrade: Time to Load Up? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
